Cardiol Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Cardiol Therapeutics R&D Spending Growth & History (CRDL)
Cardiol Therapeutics's r&d spending was $14.0M for fiscal 2025.
View full Cardiol Therapeutics company overviewCardiol Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $14.0M | $6,331 | +0.05% |
| 2024 | 2024-12-31 | $14.0M | −$212,157 | −1.49% |
| 2023 | 2023-12-31 | $14.2M | −$4.7M | −24.99% |
| 2022 | 2022-12-31 | $19.0M | $8.1M | +74.44% |
| 2021 | 2021-12-31 | $10.9M | $267,570 | +2.52% |
| 2020 | 2020-12-31 | $10.6M | — | — |
Cardiol Therapeutics quarterly r&d spending
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.2M | $464,376 | +17.00% |
| Q1 2026 | 2026-03-31 | $4.9M | $1.2M | +31.72% |
| Q4 2025 | 2025-12-31 | $2.7M | — | — |
| Q3 2025 | 2025-09-30 | $4.8M | — | — |
| Q2 2025 | 2025-06-30 | $2.7M | — | — |
| Q1 2025 | 2025-03-31 | $3.8M | — | — |
Cardiol Therapeutics r&d spending trends
Over the last five fiscal years, Cardiol Therapeutics's r&d spending increased from $10.6M to $14.0M, a change of $3.4M. The latest reported quarter, Q2 2026, shows $3.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cardiol Therapeutics source filings ↗